Please login to the form below

Not currently logged in
Email:
Password:

ocrelizumab

This page shows the latest ocrelizumab news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

However, new drugs including Ocrevus (ocrelizumab) for multiple sclerosis, cancer immunotherapy Tecentriq (atezolizumab) and new haemophilia drug Hemlibra (emicizumab) acted as a buffer.

Latest news

More from news
Approximately 9 fully matching, plus 30 partially matching documents found.

Latest Intelligence

  • Tackling a formidable foe Tackling a formidable foe

    years. Route to authorisation. Roche has developed Ocrelizumab, an infusion to treat relapsing MS and become the first treatment for primary progressive MS – although it was recently refused a licence in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics